De Novo device
Sana Device
Sana Health · Prescription Audiovisual Stimulator (Avs) For Temporary Pain Relief (Adjunctive Use) (QYN, Class I) · First FDA decision Jan 16, 2026, newest Jan 16, 2026Chronic pain
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
10
Naming "Sana"
MAUDE reports
0
Brand "Sana", since 2015
PubMed studies
696
Mentioning "Sana"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Sana Device
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Sana DeviceNew device typeDe Novo
DEN250005 · Decided Jan 16, 2026 · 319 days after receipt
Device type: Prescription Audiovisual Stimulator (Avs) For Temporary Pain Relief (Adjunctive Use) (QYN) · Physical Medicine & Rehabilitation
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transanal Endoscopic Surgery (TES)Local determinationIn effectL38551Palmetto GBAUpdated Dec 13, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Sana", any status and sponsor, newest update first.
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT06655844 · 20 participants (planned) · Start Oct 4, 2024 · Primary completion Dec 31, 2026
Device: Sana Pain Reliever; Sham SPR · For: Post-treatment Lyme Disease Syndrome; Chronic Pain
Sites: New York, New York
Henry M. Jackson Foundation for the Advancement of Military MedicineAcademic, hospital or other
NCT06885554 · 60 participants (planned) · Start Oct 6, 2025 · Primary completion Jan 1, 2028
Device: SANA · For: Adjustment Disorders
Sites: San Diego, California; Wright-Patterson Air Force Base, Ohio; Fort Sam Houston, Texas
Sana HealthNot on our public-company list
NCT05394610 · 0 participants · Start Dec 2025 · Primary completion Dec 2026
Device: Sana Device · For: Fibromyalgia; Pain, Chronic; Quality of Life
7 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Sana", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QYN
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Sana"[tiab]. The summary above synthesizes these.
- Mens Sana.
Jones R · Br J Gen Pract · 2017
- [Not Available].
De Arriba Muñoz A, López Úbeda M, Rueda Caballero C, et al. · Nutr Hosp · 2016Observational Study
- Idiopathic hemihypertrophy.
Mohanna MA, Sallam AK · Saudi Med J · 2014Case Reports
- [Not Available].
Vio F, Lera L, Salinas J · Nutr Hosp · 2016
- [Not Available].
Higuera Pulgar I, Bretón Lesmes I, Carrascal Fabián ML, et al. · Nutr Hosp · 2016
- Sceptrin-Au nano-aggregates (SANA) for overcoming drug-resistant Gram-negative bacteria.
An JM, Kang S, Koh CW, et al. · Nanoscale Horiz · 2022Research Support, Non-U.S. Gov't
- A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss.
Cal K, Leyva A, Rodríguez-Duarte J, et al. · Nat Metab · 2025Randomized Controlled Trial, Clinical Trial, Phase I
- Membrane properties modulation by SanA: implications for xenobiotic resistance in Salmonella Typhimurium.
Aleksandrowicz A, Kolenda R, Baraniewicz K, et al. · Front Microbiol · 2023
- SanA is an inner membrane protein mediating Salmonella Typhimurium infection.
Stypukowska A, Kolenda R, Carolak E, et al. · Microbiol Spectr · 2025Research Support, Non-U.S. Gov't
- SanA Plays a Role in Peptidoglycan Integrity in Escherichia coli.
Yamaguchi H, Ago R, Tahara YO, et al. · Mol Microbiol · 2026Research Support, Non-U.S. Gov't
- Vida Sana y Completa: A randomized controlled trial to examine the effectiveness of diabetes prevention with and without medically supportive groceries among Latina women.
Rosas LG, Perez JA, Chen WT, et al. · Contemp Clin Trials · 2024Clinical Trial Protocol, Research Support, Non-U.S. Gov't
- Mens sana in corpore sano.
Podewils LJ, Guallar E · Ann Intern Med · 2006Comment, Editorial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.